MNPR Monopar Therapeutics

Price (delayed)

$4.36

Market cap

$15.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.3

Enterprise value

$9.23M

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of ...

Highlights
Monopar Therapeutics's quick ratio has soared by 60% YoY and by 7% from the previous quarter
The EPS has grown by 40% YoY and by 12% from the previous quarter
The equity has contracted by 22% YoY and by 19% from the previous quarter

Key stats

What are the main financial stats of MNPR
Market
Shares outstanding
3.52M
Market cap
$15.35M
Enterprise value
$9.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$7.12M
EBITDA
-$7.12M
Free cash flow
-$6.82M
Per share
EPS
-$2.3
Free cash flow per share
-$1.95
Book value per share
$1.74
Revenue per share
$0
TBVPS
$2.05
Balance sheet
Total assets
$7.18M
Total liabilities
$1.09M
Debt
$0
Equity
$6.09M
Working capital
$6.09M
Liquidity
Debt to equity
0
Current ratio
6.59
Quick ratio
6.53
Net debt/EBITDA
0.86
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-89%
Return on equity
-110.6%
Return on invested capital
N/A
Return on capital employed
-117%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNPR stock price

How has the Monopar Therapeutics stock price performed over time
Intraday
12.95%
1 week
81.67%
1 month
87.12%
1 year
43.89%
YTD
156.47%
QTD
19.45%

Financial performance

How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.49M
Net income
-$7.12M
Gross margin
N/A
Net margin
N/A
The net income has grown by 28% year-on-year and by 6% since the previous quarter
The operating income has grown by 26% YoY and by 7% from the previous quarter

Growth

What is Monopar Therapeutics's growth rate over time

Valuation

What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
2.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 40% YoY and by 12% from the previous quarter
MNPR's price to book (P/B) is 48% more than its last 4 quarters average of 1.5 but 33% less than its 5-year quarterly average of 3.3
The equity has contracted by 22% YoY and by 19% from the previous quarter

Efficiency

How efficient is Monopar Therapeutics business performance
The return on assets has declined by 12% year-on-year and by 2.9% since the previous quarter
MNPR's return on equity is down by 10% year-on-year

Dividends

What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNPR.

Financial health

How did Monopar Therapeutics financials performed over time
The current ratio has surged by 60% year-on-year and by 6% since the previous quarter
Monopar Therapeutics's quick ratio has soared by 60% YoY and by 7% from the previous quarter
The company's debt is 100% lower than its equity
The equity has contracted by 22% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.